A Dose Selection Trial of CKD-330 in Patients With Essential Hypertension

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 456 participants.

Also called NCT02206165

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 456 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02206165
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02206165. Randomized; double masking; primary purpose treatment. Start 2014-03 (registry gives no type); primary completion 2015-04 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Dose Selection Trial of CKD-330 in Patients With Essential Hypertension
Condition
Essential Hypertension
Intervention (Drug)
Candesartan 8mg
Intervention (Drug)
Candesartan 16mg
Intervention (Drug)
Amlodipine 5mg
Intervention (Drug)
Amlodipine 10mg
Lead sponsor
Chong Kun Dang Pharmaceutical (class: industry)

Record details

Record id
cardio:ct-nct02206165
Content hash
ea1a0ee0f49fae86484cb15db41a3856cb4ab691e7f553cadff9b5ea6199c53b